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Abstract
Background: A stability-indicating reversed-phase high-performance liquid chromatography (HPLC) method with a
high sensitivity was developed for the determination of silodosin (SIL) in the presence of hydrochlorothiazide (HCT)
as an internal standard.
Methods: Chromatographic separation of SIL and IS were successfully achieved on an Agilent ZORBAX CN column
with an isocratic mobile phase composed of a mixture of methanol:acetonitrile:ammonium acetate (pH 4.0; 0.015 M)
(40:30:30, v/v/v) at a flow rate of 1.3 mL min−1. The drugs were quantified using a photodiode array detector set at a
wavelength of 270 nm. The reversed-phase HPLC method has been validated as per International Conference on
Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines to
determine SIL in pharmaceutical dosage form.
Results: The proposed method showed a good linearity in the concentration range of 4.0–600.0 μM with a lower
detection limit of 85.0 nM under optimized conditions. The statistical performance of the fully validated HPLC method
was compared to our developed sensitive spectrofluorimetric method, and the performance results of the proposed
HPLC method were considerably satisfactory. The validated method was successfully applied to quantify the SIL in
capsules, and the corresponding recovery value was found to be 99.5 %.
Conclusions: The validated HPLC method may be a promising alternative analytical tool for routine analysis of SIL in
pharmaceutical samples.
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Background
Silodosin (SIL) is a new selective α1-adrenoreceptor an-
tagonist in alpha-blocker class with a high pharmaco-
logic selectivity as shown in Scheme 1 (Sweetman 2009).
α1-adrenoreceptor antagonists were widely used in the
treatment of lower urinary tract symptoms resulting
from benign prostatic hyperplasia (BPH). BPH is a com-
mon disorder of the urogenital tract for at least 50 % of
men aged over 50 years (Goi et al. 2015). At this point,
SIL has been proven to advanced relieve the muscles in
the prostate by reducing lower urinary tract symptoms
related to BPH (Goi et al. 2015; Yoshida et al. 2007).
Therefore, a reliable and precise determination method
is highly important for the analysis of SIL in pharma-
ceutical or clinical samples.
The literature revealed that various analytical methods
have been reported to determine the SIL in pharmaceut-
ical or clinical samples including UV spectrophotometry
(Jahan and Malipatil 2014b), spectrofluorimetry (Bhamre
and Rajput 2014), high-performance liquid chromatog-
raphy (HPLC) (Jahan and Malipatil 2014a ; Aneesh and
Rajasekaran 2012; Vali et al. 2012), high-performance
thin-layer chromatography (Sayana et al. 2012), ultra
high-performance liquid chromatography (UHPLC) (Shaik
et al. 2014; Prasad et al. 2012) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) (Zhao et al. 2009)
and electrochemicalsensing (Er et al. 2015) methods. Re-
cently, the authors have attached great importance de-
velop the sensitive and reliable analytical methods for
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determination of biological and drug molecules at
nano-molar levels. In this point, we thought that an ef-
fective and highly sensitive analytical tool such as
HPLC is required with a short response time for SIL
assay. In addition, the spectrophotometric approach is
also preferred especially in the detection of drug mole-
cules due to its many advantages such as cost effective-
ness, easy operation, high sensitivity and repeatability,
rapid response time and low detection limit (Tekkeli
and Önal 2011; Walash et al. 2013). The present study
has indicated accurate and efficient analytical methods
based on reversed-phase HPLC and spectrofluorimetry




SIL powder was gifted from Recordati Pharm. Company.
Urorec® (containing 8.0 mg SIL per capsule) capsules
were purchased from a local market in Ankara, Turkey.
The internal standard (IS) was used as a hydrochlorothi-
azide (HCT) in HPLC measurements. The methanol and
acetonitrile solutions for HPLC studies were purchased
from J.T. Baker (Phillipsburg, NJ) with HPLC grade. The
other chemicals and reagents were purchased from
Sigma-Aldrich Company (Germany) and were of analyt-
ical grade. All solutions and mobile phase were prepared
with ultrapure water using Waters Milli-Q Plus purifica-
tion system.
Instrumentation and conditions
HPLC analyses were performed by an Agilent 1100 series
LC system (Agilent Technologies, Wilmington, USA)
equipped with an Agilent series G-1315B diode-array de-
tector (DAD), G-1313A ALS autosampler, G1311A Quat
pump and G1379A degasser. Chromatographic separation
was performed on a Agilent ZORBAX CN column (re-
versed-phase) (150 mm× 4.6 mm, 5 μM) in isocratic
mode. Data were collected and processed by the use of
Agilent ChemStation. The mobile phase consisted of a
mixture of aqueous 0.015 M ammonium acetate (pH
4.0):methanol:acetonitrile in the ratio (30:40:30, v/v/v).
The pH of the ammonium acetate was adjusted to 4.0 by
addition of NaOH and HCl, and the mixture was pumped
at 25 °C with a flow rate of 1.3 mL min−1. The detection
was achieved at 270 nm, and the injection volume was
10 μL. The mobilephase mixture was filtered through a
0.45μm membrane filter (Millipore, Bedford, MA) and de-
gassed under ultrasonic bath before HPLC analysis. The
quantification of SIL was based on peak area ratio using
IS.
Fluorescence spectra were measured by Agilent Cary
Eclipse spectrofluorometer (CA, USA) equipped with a
Xenon flash lamp. The slit widths for excitation and
emission monochromators were fixed at 10 nm. All
measurements were performed in a 1.0cm quartz cell at
room temperature (25 °C).
Scheme 1 Molecular structure of SIL
Fig. 1 Effect of pH on the fluorescence intensity of SIL (a) in methanol:water (1:1, v/v). Effect of the excitation wavelength on the fluorescence
intensity of SIL in pH 6.0 phosphate buffer (b)
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Analytical procedure
Preparation of standard solutions
Fifty milligrams each of standard SIL and HCT powder
were accurately weighed and dissolved in a 100-mL mix-
ture of methanol:water (1:1, v/v) by sonication for
10 min. The SIL standard solutions were diluted by the
mixture of methanol:water (1:1, v/v) and phosphate
buffer (pH 6.0) to obtain the required workingrange
concentrations for HPLC and spectrofluorimetry, respect-
ively. Each of the SIL standard solution contains 25 ppm
HCT solution during HPLC analysis. The solutions were
filtered through a 0.45μm membrane filter before injection
into the HPLC system.
Preparation of Urorec® capsules
For both HPLC and spectrofluorimetry, ten Urorec® cap-
sules were carefully weighed and powdered to get a
homogenous fine powder in a mortar. An appropriate
weight of this powder equivalent to one capsule content
was weighed, transferred into the calibrated flask and then
dissolved in the mixture of methanol:water (1:1, v/v) in an
ultrasonic bath. The final mixture was filtered by the use
of a 0.45μm membrane filter, and the filtrate was diluted
with the mixture of methanol:water (1:1, v/v) and phos-
phate buffer solution (pH 6.0) to obtain the certain con-
centration in the linearity range of SIL for HPLC and
spectrofluorimetry, respectively.
Forced degradation and stability-indicating tests
Ten milligrams each of standard SIL and HCT were dis-
solved to prepare the stock solution in a 25mL mixture of
methanol:water (1:1, v/v) by sonication for 10 min. After
forced degradation process, each solution was filtered
through a 0.20μm PTFE syringe filter before injection into
the HPLC system
Acidic degradation
In the presence of IS, 2.5 mL of 1.0 M HCl was added to
7.5 mL stock solution, and the mixture was kept at 80 °
C for 1 h under reflux, cooled and neutralized with
1.0 M HCl to pH 7.0. Then, 6.25 mL of the solution was
made up to 25 mL with ultrapure water. Finally, the so-
lution was filtered through a 0.20μm PTFE syringe
filter.
Alkaline degradation
In the presence of IS, 2.5 mL of 1.0 M NaOH was added
to 7.5 mL stock solution, and the mixture was kept at
80 °C for 1 h under reflux, cooled and neutralized with
1.0 M NaOH to pH 7.0. Then, 6.25 mL of the solution
was made up to 25 mL with ultrapure water. Finally, the
solution was filtered through 0.20-μm PTFE syringe
filter.
Oxidative degradation
In the presence of IS, 2.5 mL of 5 % H2O2 was added to
7.5 mL stock solution, and the mixture was kept at 80 °C
for 1 h under reflux then cooled, and the volume of the
mixture was made up to 25 mL with ultrapure water. Fi-
nally, the solution was filtered through 0.20-μm PTFE syr-
inge filter.
Thermal degradation
Ten milligrams each of SIL and HCT powders were kept
at 80 °C for 24 h. After that, each powder was dissolved
in a mixture of methanol:water (1:1, v/v). An aliquot of
these solutions was dissolved to get a required solution
consisting of 50 ppm SIL and 25 ppm HCT. The solu-
tion was filtered through 0.20-μm PTFE syringe filter.
Results and discussion
Optimization of HPLC conditions
Firstly, HPLC conditions were optimized to obtain a de-
sired peak with high purity and resolution. Therefore,
the various parameters affecting the peak shape, retention
Table 1 System performance parameters obtained by HPLC
for SIL
Parameters HPLC Reference value
(Center for Drug Evaluation
and Research (CDER) 1994)
Retention time, tr 2.47
Capacity factor, K′ 0.789 K′ > 2.0
Resolution, Rs 7.727 Rs > 2.0
Selectivity, α 6.771 α > 1.0
Theoretical plates,
N (plates/column)
5819 N > 2000
Tailing factor, T 1.11 T ≤ 2.0
Fig. 2 HPLC chromatograms of a standard SIL solution at increasing
concentrations in the range of 4.0 (a)–600.0 (k) μM on a Agilent
ZORBAX CN column using acetonitrile:methanol:acetate buffer (pH 4.0)
(30:40:30, v/v/v) as a mobile phase at a flow rate of 1.3 mL min−1 (Inset:
the zoomed chromatograms at increasing SIL concentrations
from 4.0 to 50.0 μM)
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time and resolution of SIL were investigated in detail.
The separation efficiency of Agilent ZORBAX CN column
(150 mm× 4.6 mm, 5 μm) was compared to the mono-
lithic column (Supelco® C18; 150 mm× 4.6 mm, 5 μm) for
the determination of SIL under the same conditions,
and the proposed column was chosen for the further
optimization parameters.
During our preliminary experiments, the series of
aqueous mobile phases containing buffer solutions with
the different pH values in combination with different or-
ganic modifiers including the different ratios of aceto-
nitrile, methanol and ammonium acetate were tested for
obtaining the optimum separation conditions. Aceto-
nitrile, methanol and ammonium acetate were selected as
the eluents. The chromatographic analysis time of SIL was
shortened with high organic solvent content, and also, the
buffer solutions in the mobile phase ensured stable chro-
matographic retention times preventing broad peaks.
The effect of the mobilephase pH on the retention
time and peak shape of the analyte was studied espe-
cially in the acidic region. The best retention time and
peak shape of SIL was achieved at pH 4.0 acetate buffer.
The best separation was achieved with the mobile phase
consisting of methanol:acetonitrile:acetate buffer (pH
4.0) (40:30:30, v/v/v). HCT was chosen as the IS as its
retention time did not prolong the analysis time and in-
dicated no interference effect on the chromatographic
peak of SIL. The calibration curves of SIL for HPLC ana-
lysis were constructed by plotting the peak area ratio of
drug molecule to IS against the concentration of the
drug.
Fig. 3 Fluorescence spectra of SIL at increasing concentrations in the range of 0.2–36.4 μM at 460 nm after excitation of 330 nm in pH 6.0 phosphate
buffer (the concentration range: 0.2 (b)–1.0 (f) μM (b); 1.0 (g)–36.4 (p) μM (a)). Fluorescence spectrum of blank solution ((a) and (f)) containing
methanol:water: pH 6.0 phosphate buffer). The calibration curve of SIL obtained by spectrofluorimetry (c) in pH 6.0 phosphate buffer
Table 2 Validation results obtained from HPLC for the
quantitative determination of SIL
Parameters HPLC
Linearity range (μM)a 4.0–600.0
Slopeb 5.8625
Interceptb 0.0050
Correlation coefficient (R2) 0.9988
LOD (nM) 85.2
LOQ (nM) 284.0
Repeatability of peak area, (RSD %)c 0.12
Repeatability of peak area, (RSD %)d 0.19
aAverage of three determinations
bRpa (a.u.) =m CSL (μM) + b where C is the concentration and IFL is the
fluorescence intensities
cIntra-day measurements—each value is the mean of five experiments
dInter-day measurements—each value is the mean of five experiments
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Optimization of spectrofluorimetry conditions
In the second part of study, SIL exhibited the intense na-
tive fluorescence in phosphate buffer (pH 6.0) at 460 nm
after an excitation of 330 nm as shown in Fig. 1. This
feature gives a chance to develop a novel spectrofluori-
metric method for determination of SIL in its pharma-
ceutical dosage forms. In this point, the various
experimental parameters affecting the fluorescence in-
tensity of SIL were carefully studied and the developed
method was optimized in detail.
Effect of pH and excitation wavelength on fluorescence
intensity
It is a known fact that the intensities of fluorescent mol-
ecules are connected with the pH value of the medium
and excitation wavelength. The influence of pH on the
fluorescence intensity of SIL was investigated using dif-
ferent pH values in the range from 2.0 to 10.0 with the
three replicate measurements. The maximum fluores-
cence intensity of SIL was observed at pH 6.0 as shown
in Fig. 1a. The effect of the excitation wavelength on
fluorescence intensity was also performed with three
replicate measurements in the range of 310–360 nm. It
was found that maximum fluorescence intensity of SIL
was obtained at excitation wavelength of 330 nm in pH
6.0 phosphate buffer as shown in Fig. 1b.
Method validation
Chromatographic and spectrofluorimetric approaches
have been useful techniques for the determination of
drug or biologically important molecules in real samples
for many years, and these techniques offer a simple way
to quantify the drug molecules especially in pharmaceut-
ical formulations (Belal et al. 2013; Antunes et al. 2013).
Therefore, the presented study aims to develop validated
analytical methods for the determination of SIL in
pharmaceutical samples.
To evaluate the analytical performance of our proposed
methods, the various analytical parameters (linearity,
accuracy, precision, etc.) were investigated in detail under
optimized conditions (International Conference on Har-
monisation (ICH) 2005). The chromatographic analysis of
SIL was successfully performed using the proposed
method (Agilent ZORBAX CN column; 150 mm×
4.6 mm× 5 μm; sample volume of 10 μL; a mobile phase
composed of acetonitrile, methanol and acetate buffer
(pH 4.0); (30:40:30, v/v/v) at a flow rate of 1.3 mL min
−1; ambient temperature; detection wavelength of
270 nm). System suitability parameters were performed
prior to analysis based on United States Pharmacopeia
(USP) (The United States Pharmacopeia 2011). These
parameters including tailing factor, peak resolution and
selectivity, retention time and number of theoretical
plates for the proposed method were evaluated, and the
obtained values were in the acceptable ranges according
to USP requirements as shown in Table 1 (Center for
Drug Evaluation and Research (CDER) 1994).
Figure 2 indicates that peak area ratio (Rpa) of SIL was
linearly increased with the SIL concentration in the
range from 4.0 to 600.0 μM with a detection limit of
Table 4 The comparison of developed analytical methods used in determination of SIL
Method Linearity range (μM) LOD Reference
UV 8.1–40.4 0.031 μM (Jahan and Malipatil 2014b)
Spectrofluorimetry 0.02–2.0 6.1 nM (Bhamre and Rajput 2014)
HPLC 20.2–60.5 6.16 μM (Jahan and Malipatil 2014a)
RP-HPLC 20.2–121.0 11.00 μM (Aneesh and Rajasekaran 2012)
HPLC (chiral) 0.26–9.1 80.7 nM (Vali et al. 2012)
UHPLC 0.5–3.0 0.161 μM (Shaik et al. 2014)
LC-MS/MS 0.001–0.1 0.30 nM (Zhao et al. 2009)
GRP/AuNPs/GCE 0.01–3.3 3.80 nM (Er et al. 2015)
Spectrofluorimetry 0.2–36.4 7.7 nM Our study
RP-HPLC 4.0–600.0 85.2 nM Our study
Table 3 Validation results obtained from spectrofluorimetry for
the quantitative determination of SIL
Parameters Spectrofluorimetry
Wavelength (nm) λex = 330, λem = 460
Linearity rangea (μM) 0.2–36.4
Slopeb 26.993
Interceptb 4.4526
Correlation coefficient (R2) 0.9975
LOD (nM) 7.70
LOQ (nM) 26.80
Repeatability of peak intensity (RSD %)c 0.48
Repeatability of peak intensity (RSD %)d 0.85
aAverage of three determinations
bIFL (a.u.) =m CSL (μM) + b where C is the concentration and IFL is the
fluorescence intensities
cIntra-day measurements—each value is the mean of five experiments
dInter-day measurements—each value is the mean of five experiments
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85 nM (S/N = 3) under optimized conditions. The valid-
ation results obtained from HPLC are presented in
Table 2. The related regression equation is as follows:
Rpa ¼ 5:8625 CSILðμMÞ − 0:0050 ðR2 ¼ 0:9988Þ
ð1Þ
SIL analysis was performed at 460 nm after excitation
at 330 nm in pH 6.0 phosphate buffer for the proposed
spectrofluorimetric method. The fluorescence signal at
370 nm was caused from a blank solution system con-
sisting of methanol:water:phosphate buffer (pH 6.0)
(10:10:80, v/v/v). The fluorescence intensity (IFL) of SIL
was observed to be a good linear relationship with the
increasing concentration in the range of 0.2–36.4 μM as
shown in Fig. 3. The regression equation for SIL is as
follows:
IFL ¼ 26:993 CSILðμMÞ þ 4:4526 R2 ¼ 0:9975
 
ð2Þ
The limit of detection (LOD) for SIL was found to be
7.7 nM calculated from related equation (S/N = 3). The
similar study claimed that a narrow working range such
as 0.1–3.0 μg mL−1 for SIL are obtained at the excitation
wavelength of 340 nm, and the best results for SIL were
obtained at the excitation wavelength of 272 nm
(Bhamre and Rajput 2014). Contrary to these results, the
fluorescence intensity of SIL was gradually decreased
with decreasing excitation wavelength from 330 to the
less excitation wavelength in our study as shown in
Fig. 1b. In this point, we presented a highly large linear
range for SIL at the excitation wavelength of 330 nm in
the buffer solution system.
The validation results including linearity, precision and
accuracy of our proposed spectrofluorimetric method are
presented in Table 3. The repeatability of results obtained
by spectrofluorimetry for inter- and intra-day precisions
was examined in the standard SIL solution at the same
conditions. The relative standard deviation (RSD) values
for inter- and intra-day precision were calculated to be
0.48 and 0.85 %, respectively. The results indicated that
the proposed method has a highly satisfactory repeatability
for the determination of SIL.
A comparison between the analytical parameters of the
present methods and some previous methods reported in
the literature for the determination of SIL is presented in
Table 4. The proposed methods have sufficiently low LOD
Fig. 4 HPLC chromatograms of SIL in the presence of HCT (a), exposed to acidic (b), alkaline (c), oxidative (d) and thermal (e) degradations
Table 5 Analysis of SIL in capsules using proposed methods
Parameters Spectrofluorimetry HPLC
Claimed (mg) 8.00 8.00
Found (mg) 7.85 7.96
RSD (%) 4.50 0.51
Average recovery (%) 98.50 99.50




Critical value of t = 2.78 at 95 % confidence level (n = 5)
Critical value of F = 6.39 at 95 % confidence level (n1 = 5 and n2 = 5)
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values compared to previously reported values for the
detection of SIL.
Analytical applications
Silodosin assay in Urorec® capsules
Real-sample analysis is highly important to evaluate the
system suitability of the proposed method towards the
drug molecule with an acceptable recovery. Hence,
pharmaceutical capsules (Urorec®) were selected as a real
sample to show the applicability of our proposed
methods. The results obtained from HPLC and spectro-
fluorimetry showed that the amount of SIL in capsules
by both proposed methods is in good agreement with
the labelled claim as summarized in Table 5. No interfer-
ing peaks were observed in the recorded chromatograms
and fluorescence spectra indicating that there is no
interference effect resulting from excipients used in the
production of capsules and buffer medium. The recovery
values were found to be 98.5 and 99.5 % for spectro-
fluorimetry and HPLC, respectively. The corresponding
RSD values were well below 5.0 % indicating the pro-
posed methods are sufficiently accurate and precise for
quantitative purposes in analytical applications. Besides,
statistical performance of the spectrofluorimetric results
was compared with the results of the developed HPLC
method using Student t and F tests at a 95 % confidence
level as shown in Table 5.
Forced degradation behaviour
Forced degradation experiments were also performed to
evaluate the stability and specificity of the proposed
HPLC method in different mediums. The acidic, alkaline
and oxidative degradation of SIL in the presence of IS
were studied by treating with 1.0 M HCl/1.0 M NaOH/
5 % H2O2 solutions at 80 °C for 1 h, respectively. The
thermal degradation of SIL in the presence of IS were
also studied by heating the SIL solution at 80 °C for
24 h. The whole degradation products were observed at
approximately 1.50 and 2.50 min for HCT and SIL, re-
spectively, in all proposed stress conditions as shown in
Fig. 4. The stress studies showed no significant difference
in terms of retention times of drugs, and no interfering
peaks were observed within the retention time under
alkaline, acidic, oxidative and thermal degradation condi-
tions. Considering all these data, SIL was successfully
separated from all the degradation products which were
confirmed by the resolution values calculated from each
chromatogram (Rs > 1.5) (Table 6).
Conclusions
A highly sensitive and effective validated reversed-phase
HPLC method was successfully developed with a low
LOD value for SIL assay. The SIL in the presence of HCT
were subjected to forced degradation under several stress
conditions. The satisfactory results were achieved from
degradation studies, which revealed that the method was
stability indicating. Besides, the spectrofluorimetric ap-
proach has drawn attention with satisfactory results in
the detection of SIL in a pharmaceutical sample. The
proposed methods have significant advantages such as
rapid, sensitive, not needing a fluorescent agent and de-
rivatization reactions, good reproducibility and cost ef-
fectiveness. The results showed that the developed
analytical methods could be a very promising alterna-
tive for the determination of SIL in routine drug and
clinical application.
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